UBS analyst Joshua Spector lowered the firm’s price target on Chemours (CC) to $17 from $18 and keeps a Buy rating on the shares. Chemours reported better than feared EBITDA, but the dividend cut was unexpected, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC: